产品说明书
Famciclovir
 |
同义名 : | 泛昔洛韦 ;BRL 42810 |
| CAS号 : | 104227-87-4 | |
| 货号 : | A643497 | |
| 分子式 : | C14H19N5O4 | |
| 纯度 : | 97% | |
| 分子量 : | 321.332 | |
| MDL号 : | MFCD00866964 | |
| 存储条件： |
粉末 Keep in dark place,Inert atmosphere,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(326.77 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 50 mg/mL(155.6 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Famciclovir is the prodrug of penciclovir, a guanosine analogue that inhibits viruses of the alpha sub-family of the Herpesviridae, as well as hepatitis B virus. It is indicated for management of mucocutaneous herpes simplex virus disease and acute herpes zoster, and has been investigated for management of hepatitis B virus infection[3]. Famciclovir (Famvir) is the oral prodrug of penciclovir, an agent that has demonstrated antiviral activity against herpes simplex viruses, type 1 (HSV-1) and 2 (HSV-2) [which cause orolabial and/or genital herpes simplex], and against varicella zoster virus (VZV) [a reactivation of which leads to herpes zoster][4]. Famciclovir is an effective treatment of immunocompetent patients with acute herpes zoster (shingles) caused by VZV(varicella zoster virus). Famciclovir has therapeutic efficacy similar to that of oral aciclovir (acyclovir) in attenuating the acute signs and symptoms of infection (including pain during the acute phase of infection). In immunocompetent patients with recurrent genital herpes infection, suppressive treatment with oral famciclovir effectively prolonged the time to recurrence of symptomatic episodes of infection compared with placebo. In addition, famciclovir significantly reduced the duration of viral shedding, accelerated healing of genital herpes lesions and reduced the duration of symptoms[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03120962 | Herpes Zoster ... 展开 >> Post-herpetic Neuralgia 收起 << | Not Applicable | Not yet recruiting | November 2020 | - |
| NCT00477334 | Genital Herpes | Phase 4 | Completed | - | - |
| NCT00219310 | Recurrent Genital Herpes (RGH) | Phase 4 | Completed | - | United States, New Jersey ... 展开 >> Novartis Pharmaceuticals East Hanover, New Jersey, United States 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.11mL 0.62mL 0.31mL |
15.56mL 3.11mL 1.56mL |
31.12mL 6.22mL 3.11mL |
| 参考文献 |
|---|